|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Genitourinary cancer
Early Plasma
Circulating Tumor DNA
as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer
Xiaochen Fei, Xinxing Du, Yiming Gong, Jiazhou Liu, Liancheng Fan, Jiayi Wang, Yanqing Wang, Yinjie Zhu, Jiahua Pan, Baijun Dong, Wei Xue
Cancer Res Treat.
2023;55(3):969-977. Published online March 2, 2023 DOI:
https://doi.org/10.4143/crt.2022.1557
Utilizing Plasma
Circulating Tumor DNA
Sequencing for Precision Medicine in the Management of Solid Cancers
Yongjun Cha, Sheehyun Kim, Sae-Won Han
Cancer Res Treat.
2023;55(2):367-384. DOI:
https://doi.org/10.4143/crt.2023.446
Clinical
Circulating Tumor DNA
Testing for Precision Oncology
Hyunji Kim, Kyoung Un Park
Cancer Res Treat.
2023;55(2):351-366. DOI:
https://doi.org/10.4143/crt.2022.1026
Hematologic malignancy
Circulating Tumor DNA
–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas
Seok Jin Kim, Yeon Jeong Kim, Sang Eun Yoon, Kyung Ju Ryu, Bon Park, Donghyun Park, Duck Cho, Hyun-Young Kim, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Won Seog Kim
Cancer Res Treat.
2023;55(1):291-303. Published online March 2, 2022 DOI:
https://doi.org/10.4143/crt.2022.017
Cited By 2
Lung and Thoracic cancer
The Feasibility of Using Biomarkers Derived from
Circulating Tumor DNA
Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer
Yu Feng, Yutao Liu, Mingming Yuan, Guilan Dong, Hongxia Zhang, Tongmei Zhang, Lianpeng Chang, Xuefeng Xia, Lifeng Li, Haohua Zhu, Puyuan Xing, Hongyu Wang, Yuankai Shi, Zhijie Wang, Xingsheng Hu
Cancer Res Treat.
2022;54(3):753-766. Published online October 5, 2021 DOI:
https://doi.org/10.4143/crt.2021.905
Cited By 1
Hematologic malignancy
Plasma
Circulating Tumor DNA
in Patients with Primary Central Nervous System Lymphoma
Sang Eun Yoon, Yeon Jeong Kim, Joon Ho Shim, Donghyun Park, Junhun Cho, Young Hyeh Ko, Woong-Yang Park, Yeung-Chul Mun, Kyoung Eun Lee, Duck Cho, Won Seog Kim, Seok Jin Kim
Cancer Res Treat.
2022;54(2):597-612. Published online July 23, 2021 DOI:
https://doi.org/10.4143/crt.2021.752
Cited By 4
Lung cancer
A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating
EGFR
Mutations in
Circulating Tumor DNA
: LiquidLung-O-Cohort 1
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Cancer Res Treat.
2021;53(1):93-103. Published online September 21, 2020 DOI:
https://doi.org/10.4143/crt.2020.459
Cited By 2
Clinical Implications of
Circulating Tumor DNA
from Ascites and Serial Plasma in Ovarian Cancer
Mi-Ryung Han, Sug Hyung Lee, Jung Yoon Park, Hyosun Hong, Jung Yoon Ho, Soo Young Hur, Youn Jin Choi
Cancer Res Treat.
2020;52(3):779-788. Published online February 28, 2020 DOI:
https://doi.org/10.4143/crt.2019.700
Cited By 15
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from
Circulating Tumor DNA
: LiquidLung-O-Cohort 2
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Cancer Res Treat.
2019;51(2):777-787. Published online September 7, 2018 DOI:
https://doi.org/10.4143/crt.2018.387
Cited By 30
Circulating Tumor DNA
Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes
Jin Ju Kim, Hye Min Kim, Hongkyung Kim, Soo-Jeong Kim, Seung-Tae Lee, Jong Rak Choi, Saeam Shin, Doh Yu Hwang
Received May 17, 2023 Accepted July 15, 2023 Published online July 17, 2023
DOI:
https://doi.org/10.4143/crt.2023.667
[Accepted]
1
Journal Impact Factor 4.6